Clinical Trial Update: Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation and expansion study of IPN60090 in patients with advanced solid tumors; the study has terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• IPN60090

Snippet

Sponsor: Ipsen | Conditions: Solid Tumor | Phase 1 | Status: TERMINATED | Results posted: 2021-11-22